Stay updated with breaking news from Nasdaq Arqt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eight brokerages that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year target price among […]
WESTLAKE VILLAGE, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company...
Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) were down 4.6% during trading on Thursday . The stock traded as low as $10.17 and last traded at $10.30. Approximately 1,029,580 shares were traded during mid-day trading, a decline of 81% from the average daily volume of 5,305,673 shares. The stock had previously closed […]
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report)’s stock price was down 7.7% during mid-day trading on Monday . The company traded as low as $10.06 and last traded at $10.29. Approximately 1,248,266 shares were traded during mid-day trading, a decline of 77% from the average daily volume of 5,378,077 shares. The stock had previously […]
Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement ...